<DOC>
	<DOCNO>NCT00685126</DOCNO>
	<brief_summary>The purpose study compare efficacy two dose level levalbuterol compare one dose level racemic albuterol pediatric subject age birth 48 month old .</brief_summary>
	<brief_title>Study Levalbuterol Racemic Albuterol Pediatric Subjects With Reactive Airways Disease ( RAD )</brief_title>
	<detailed_description>A double-blind , randomize , active-controlled , multicenter , parallel-group trial levalbuterol pediatric subject present acute reactive airway disease . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Bronchial Hyperreactivity</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Subject , male female , must age birth 48 month inclusive time consent . Subject must experience least one previous episode history reactive airway disease . Subject must Oxygen saturation ≥ 90 % room air 2 L/min supplemental Oxygen . Subject participate investigational drug study within 30 day prior study start , previously participate study . Subject known sensitivity levalbuterol racemic albuterol , include Ventolin® excipients contain formulation . Subject use prescription drug levalbuterol racemic albuterol sulfate administration contraindicate .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Months</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>RAD</keyword>
	<keyword>Reactive Airways Disease</keyword>
	<keyword>Levalbuterol</keyword>
	<keyword>Racemic albuterol</keyword>
</DOC>